Loading...
XNASABIO
Market cap2mUSD
Aug 30, Last price  
2.40USD
Name

ARCA Biopharma Inc

Chart & Performance

D1W1MN
XNAS:ABIO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
79.70%
Rev. gr., 5y
%
Revenues
0k
195,000545,0003,888,00046,861,00015,251,000000000000000000
Net income
-5m
L-42.32%
-52,489,000-71,611,000-130,553,000-12,301,000-29,923,000-9,138,000-8,420,000-5,364,000-4,320,000-6,939,000-9,689,000-11,445,000-16,463,000-18,490,000-7,931,000-5,482,000-9,738,000-19,231,000-9,256,000-5,339,000
CFO
-5m
L-54.05%
-50,112,000-59,035,000-37,060,000-45,958,000-46,508,000-41,726,000-8,324,000-6,959,000-4,078,000-5,288,000-9,406,000-10,534,000-14,987,000-17,472,000-8,244,000-4,801,000-7,725,000-18,762,000-10,912,000-5,014,000
Dividend
Aug 29, 20241.613 USD/sh
Earnings
Jan 30, 2025

Profile

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
URL
https://arcabio.com/
IPO date
Jul 21, 2000
Employees
5
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
7,407
10,710
19,426
Unusual Expense (Income)
NOPBT
(7,407)
(10,710)
(19,426)
NOPBT Margin
Operating Taxes
(111)
(670)
(91)
Tax Rate
NOPAT
(7,296)
(10,040)
(19,335)
Net income
(5,339)
-42.32%
(9,256)
-51.87%
(19,231)
97.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
24,070
BB yield
-80.52%
Debt
Debt current
103
100
Long-term debt
612
560
766
Deferred revenue
Other long-term liabilities
(204)
Net debt
(36,819)
(41,782)
(52,493)
Cash flow
Cash from operating activities
(5,014)
(10,912)
(18,762)
CAPEX
(2)
(43)
Cash from investing activities
(2)
(43)
Cash from financing activities
23,093
FCF
(7,185)
(9,923)
(19,371)
Balance
Cash
37,431
42,445
53,359
Long term investments
Excess cash
37,431
42,445
53,359
Stockholders' equity
(188,727)
(183,388)
(173,462)
Invested Capital
226,313
225,444
224,988
ROIC
ROCE
EV
Common stock shares outstanding
14,416
14,410
13,904
Price
1.70
-28.27%
2.37
10.23%
2.15
-46.38%
Market cap
24,507
-28.24%
34,152
14.25%
29,893
58.27%
EV
(12,312)
(7,630)
(22,600)
EBITDA
(7,296)
(10,596)
(19,335)
EV/EBITDA
1.69
0.72
1.17
Interest
675
Interest/NOPBT